• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Corcept Therapeutics (NQ: CORT )

    47.15 -1.82 (-3.73%)
    Streaming Delayed Price Updated: 2:46 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Corcept Therapeutics

    < Previous 1 2 3 4 5 6 7 Next >
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
    From Corcept Therapeutics Incorporated
    Via Business Wire
    Earnings Preview: Corcept Therapeutics
    Via Benzinga
    Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
    From Corcept Therapeutics Incorporated
    Via Business Wire
    Key Takeaways From Corcept Therapeutics Analyst Ratings
    Via Benzinga
    Is NASDAQ:CORT suited for high growth investing?
    Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing? 
    Via Chartmill
    NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
    Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on the Verge of a Major Breakout as a Strong Growth Stock? 
    Via Chartmill
    Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
    NASDAQ:CORT is not too expensive for the growth it is showing. 
    Via Chartmill
    Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
    Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
    Via Benzinga
    Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
    Via Benzinga
    NASDAQ:CORT is not too expensive for the growth it is showing.
    Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced. 
    Via Chartmill
    NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
    Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. 
    Via Chartmill
    For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
    Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
    CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
    Via Chartmill
    NASDAQ:CORT is not too expensive for the growth it is showing.
    Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    Unveiling 8 Analyst Insights On Corcept Therapeutics
    Via Benzinga
    6 Analysts Have This To Say About Corcept Therapeutics
    Via Benzinga
    CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
    CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
    CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating. 
    Via Chartmill
    Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
    For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
    Via Chartmill
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
    Via InvestorPlace
    Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
    Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge. 
    Via InvestorPlace
    Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
    CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is showing good growth, while it is not too expensive. 
    Via Chartmill
    Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
    Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
    From Corcept Therapeutics Incorporated
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.